44,514 Shares in Pharvaris (NASDAQ:PHVS) Bought by Woodline Partners LP

Woodline Partners LP acquired a new stake in Pharvaris (NASDAQ:PHVS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 44,514 shares of the company's stock, valued at approximately $853,000. Woodline Partners LP owned 0.09% of Pharvaris as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Soleus Capital Management L.P. increased its holdings in Pharvaris by 36.2% in the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock valued at $15,617,000 after buying an additional 216,483 shares during the last quarter. FMR LLC boosted its position in shares of Pharvaris by 3.6% during the 4th quarter. FMR LLC now owns 5,395,370 shares of the company's stock worth $103,429,000 after acquiring an additional 189,714 shares in the last quarter. Octagon Capital Advisors LP increased its holdings in shares of Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock valued at $14,914,000 after acquiring an additional 157,530 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Pharvaris by 36.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after acquiring an additional 118,408 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in Pharvaris by 483.9% during the fourth quarter. Northern Trust Corp now owns 91,932 shares of the company's stock worth $1,762,000 after purchasing an additional 76,188 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have commented on PHVS. Cantor Fitzgerald dropped their price target on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. JMP Securities upped their target price on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.

Pharvaris Trading Up 8.2%

Shares of Pharvaris stock traded up $1.26 during trading on Thursday, reaching $16.72. The company's stock had a trading volume of 113,365 shares, compared to its average volume of 72,984. The company has a 50-day moving average price of $15.40 and a two-hundred day moving average price of $17.26. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $25.50. The firm has a market cap of $874.29 million, a PE ratio of -5.97 and a beta of -2.85.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09). On average, analysts predict that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.